The FDA delivered two regulatory updates affecting modestly sized but commercially meaningful indications. Vanda Pharmaceuticals won approval for Nereus (tradipitant), the first new drug specifically for motion sickness in decades, based on three pivotal trials including real‑world boat studies. Separately, the FDA accepted Axsome’s supplemental NDA for AXS‑05 for Alzheimer’s agitation and granted priority review with a PDUFA date set for April 30. Both actions will shift near‑term commercialization and clinical timelines for the companies.